Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Mycosis Fungoides Clinical Trial

Official title:

A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01134341
• Other study ID #: PDX-018
• Status: Completed
• Phase: Phase 1
• Start date: March 2010
• Est. completion date: August 2015

Study information

• Verified date: December 2019
• Source: Acrotech Biopharma LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to determine the recommended dose, safety, pharmacokinetics, and early efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or refractory CTCL.

Description:

This is a multi-center, dose-finding, Phase 1 study of pralatrexate plus bexarotene in patients who have relapsed or refractory CTCL.

Primary Objective(s):

• Determine the maximum tolerated dose (MTD) and recommended dose of pralatrexate plus bexarotene with concurrent vitamin B12 and folic acid supplementation when administered to patients who have failed prior systemic treatment.

Secondary Objective(s):

• Determine the safety profile of pralatrexate plus bexarotene when administered to patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL).

• Collect preliminary efficacy data.

• Determine the pharmacokinetic (PK) profile of pralatrexate plus bexarotene in patients who underwent plasma PK sampling

Recruitment information / eligibility

• Status: Completed
• Enrollment: 34
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Cutaneous T-cell lymphoma patients with subtypes of mycosis fungoides (MF) Stage IB or higher, Sézary syndrome, or primary cutaneous anaplastic large cell lymphoma who have failed a previous systemic treatment.

• Patients must have received at least 1 previous systemic therapy, and either progressed or not tolerated their last prior treatment regimen.

• Eastern Cooperative Oncology Group Performance Status less than or equal to 2.

• Adequate blood, liver, and kidney function as defined by laboratory tests.

• Women of childbearing potential must practice medically acceptable contraception from study treatment start until at least 30 days after the last dose of study treatment. Negative serum pregnancy test within 14 days before the first day of study treatment (not required for patients who are postmenopausal for at least 1 year or surgically sterilized). Study treatment should not be given to women who are breastfeeding.

• Males who are sexually active must agree to practice medically acceptable barrier contraception while receiving study treatment and for 30 days after the last dose of study treatment.

• Give written informed consent & privacy authorization.

Exclusion Criteria:

• If there is a history of prior malignancies other than non-melanoma skin cancer, carcinoma in situ of the cervix, localized prostate cancer, or localized thyroid cancer, patient must be disease free for at least 5 years. Patients with other prior malignancies less than 5 years before study entry may be enrolled if they received treatment resulting in complete resolution of the cancer and have no current clinical, radiologic, or laboratory evidence of active or recurrent disease.

• Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of less than 100 mm3 or detectable viral load within the past 3 months, and receiving combination anti-retroviral therapy.

• Diagnosis of Hepatitis B virus, or Hepatitis C virus with detectable viral load or immunological evidence of chronic active disease or receiving/requiring antiviral therapy.

• Active central nervous system disease requiring treatment.

• Active uncontrolled infection, underlying medical condition, or other serious illness impairing the patient's ability to receive protocol treatment.

• Discontinuation of prior oral bexarotene due to an allergic reaction or treatment-related toxicity.

• Major surgery within 2 weeks of planned start of treatment.

• Conventional or investigational chemotherapy or radiation therapy encompassing greater than 10% of bone marrow within 4 weeks prior to study treatment.

• ECP, phototherapy with PUVA, or ultraviolet (UV) therapy within 2 weeks prior to study treatment.

• Systemic corticosteroids within 3 weeks of study treatment, unless patient has been taking a continuous dose of no more than 10 mg per day of prednisone or equivalent for at least 4 weeks.

• Initiation of or change in dosage of topical corticosteroids within 3 weeks of study treatment (topical steroid use within 3 weeks is allowed provided the strength and use has been stable for at least 4 weeks).

• Investigational drugs, biologics, or devices use within 2 weeks prior to study treatment or planned use during the study.

• Monoclonal antibody within 3 months without evidence of PD.

• Use of oral retinoids, except bexarotene, within 4 weeks of study treatment or high-dose vitamin A (once daily multi-vitamin allowed).

• Previous exposure to pralatrexate.

• Uncontrolled hypercholesterolemia or hypertriglyceridemia.

Related Conditions & MeSH terms

• Cutaneous T-cell Lymphoma
• Lymphoma
• Lymphoma, Large-Cell, Anaplastic
• Lymphoma, Primary Cutaneous Anaplastic Large Cell
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Cutaneous
• Mycoses
• Mycosis Fungoides
• Primary Cutaneous Anaplastic Large Cell Lymphoma
• Sezary Syndrome

Intervention

Drug:
• Pralatrexate Injection
Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride). 10 or 15 mg/m2, depending on cohort assignment. Dose reductions allowed for protocol-specified criteria. Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met.
• Bexarotene Capsules
150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal. Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert. Administered daily until criteria for study treatment discontinuation per the protocol are met.

Dietary Supplement:
• Vitamin B12
1 mg intramuscular injection Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene).
• Folic Acid
1-1.25 mg orally Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene).

Locations

Country	Name	City	State
Italy	Ospedale Sant'Orsola - Policlinico Sant'Orsola	Bologna
United States	MD Anderson Cancer Center	Houston	Texas
United States	Memorial Sloan-Kettering Cancer Center	New York	New York
United States	University of Pittsburgh School of Medicine	Pittsburgh	Pennsylvania
United States	Stanford University School of Medicine	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Acrotech Biopharma LLC

Countries where clinical trial is conducted

United States,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Limiting Toxicity (DLT) Rate	DLT rate is the number of patients experiencing a DLT divided by number of evaluable patients and it will be summarized by dose level.	Assessed weekly through cycle 1 (weeks 1-4)
Secondary	Overall Response Rate (ORR)	best overall response is the best response recorded from the start of treatment until PD.; The objective response rate is the proportion of patients with a best overall response of either CR or PR and it will be summarized by dose level and overall.	Assessed after every 2 cycles (8 weeks) for the first 12 months, then every 4 cycles (16 weeks) until progression of disease.
Secondary	Number of Patients with Treatment-related Adverse Events (AEs) and Serious AEs (SAEs)	(CTCAE) Scale, Version 4.0 for AE grading.; Grade 3 neutropenia lasting for = 7 days or granulocyte colony-stimulating factor (G-CSF) administered.; Grade 3 thrombocytopenia.; Grade 3 treatment-related hyperlipidemia or hypothyroidism; Grade 3 study treatment-related non-hematologic toxicity	Recorded at all study visits: weekly (every 7 +/- 2 days) while on treatment and at safety follow-up (35 +/- 5 days post-last dose) or early termination visit (at time of withdrawal).
Secondary	Pharmacokinetic Parameters	This was collected during the dose-finding stage of the study. PK sampling is not included in the cohort expansion.	Sampling through 24 hours post end-injection of pralatrexate in cycle 1 dose 1 (week 1) and cycle 1 dose 3 (week 3).